34840-85-2

Basic information

• Product Name: 3-AMINO-3-(3,4-DIMETHOXY-PHENYL)-PROPIONIC ACID
• Synonyms: 3-AMINO-3-(3,4-DIMETHOXYPHENYL)PROPANOIC ACID;DL-BETA-(3,4-DIMETHOXYPHENYL)ALANINE;DL-3-AMINO-3-(3',4'-DIMETHOXYPHENYL)PROPIONIC ACID;RARECHEM AK HC T253;TIMTEC-BB SBB000651;SPECS AG-205/40088415;DL--(3,4-Dimethoxyphenyl)alanine;3-(3,4-DIMETHOXYPHENYL)-DL-BETA-ALANINE
• CAS NO: 34840-85-2
• Molecular Formula: C₁₁H₁₅NO₄
• Molecular Weight: 225.24
• Mol File: 34840-85-2.mol

Chemical Properties

• Melting Point: 223 °C (dec.)(lit.)
• Boiling Point: 217°C
• Flash Point: 183.416 °C
• Appearance: /
• Density: 1.212 g/cm³
• CAS DataBase Reference: 3-AMINO-3-(3,4-DIMETHOXY-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-3-(3,4-DIMETHOXY-PHENYL)-PROPIONIC ACID(34840-85-2)
• EPA Substance Registry System: 3-AMINO-3-(3,4-DIMETHOXY-PHENYL)-PROPIONIC ACID(34840-85-2)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 34840-85-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-3-(3,4-dimethoxy-phenyl)-propionic acid is used as a novel therapeutic candidate for the treatment of anemia. It has the potential to induce the production of gamma-globin, which in turn leads to the formation of fetal hemoglobin (HbF). 3-Amino-3-(3,4-dimethoxy-phenyl)-propionic acid can be particularly beneficial for patients suffering from anemia, as it may help improve their overall health and well-being by enhancing the oxygen-carrying capacity of their blood.

Upstream product

• 141-82-2 malonic acid 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 62334-34-3 C₉H₁₁NO₂ 
• 5763-61-1 3,4-dimethoxybenzylamine 

Downstream Products

• 167887-02-7 3-phthalimido-3-(3',4'-dimethoxyphenyl)propionic acid 
• 914099-75-5 7-{3-[2-carboxy-1-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-benzoylamino}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 914099-79-9 7-{3-[2-carboxy-1-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-5-nitro-benzoylamino}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 34841-03-7 methyl 3-amino-3-(3',4'-dimethoxyphenyl)propionate hydrochloride 
• 1445597-07-8 methyl 3-(4,5-dimethoxy-2-nitrophenyl)-3-(2,2,2-trifluoroacetamido)propanoate 
• 683218-30-6 N-(9-fluorenylmethyloxycarbonyl)-3-amino-3-(4,5-dimethoxy-2-nitrophenyl)propionic acid 
• 60117-24-0 H-Tyr-Gly-Gly-Phe-Leu-NH₂ 
• 1445597-06-7 methyl 3-(3,4-dimethoxyphenyl)-3-(2,2,2-trifluoroacetamido)propanoate 
• 1078052-80-8 methyl 5-(tert-butoxycarbonylamino)-5-(3,4-dimethoxyphenyl)-3-oxopentanoate 
• 1078052-82-0 C₂₃H₃₅NO₇ 
• 1078052-81-9 C₂₃H₃₅NO₇ 
• 1078052-83-1 C₁₇H₂₃NO₄ 
• 1078052-84-2 6-(3,4-dimethoxyphenyl)-4-isobutoxy-5,6-dihydropyridin-2(1H)-one 
• 1078052-85-3 C₁₇H₂₅NO₄ 

Relevant articles and documents

First synthesis of racemic trans propargylamino-donepezil, a pleiotrope agent able to both inhibit AChE and MAO-B, with potential interest against Alzheimer’s disease

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease towards which pleiotropic approach using Multi-Target Directed Ligands is nowadays recognized as probably convenient. Among the numerous targets which are today validated against AD, acetylcholinesterase (ACh) and Monoamine Oxidase-B (MAO-B) appear as particularly convincing, especially if displayed by a sole agent such as ladostigil, currently in clinical trial in AD. Considering these results, we wanted to take benefit of the structural analogy lying in donepezil (DPZ) and rasagiline, two indane derivatives marketed as AChE and MAO-B inhibitors, respectively, and to propose the synthesis and the preliminary in vitro biological characterization of a structural compromise between these two compounds, we called propargylaminodonepezil (PADPZ). The synthesis of racemic trans PADPZ was achieved and its biological evaluation established its inhibitory activities towards both (h)AChE (IC50 = 0.4 μM) and (h)MAO-B (IC50 = 6.4 μM).

ISOINDOLE DERIVATIVE

Disclosed is a compound of formula (I) and a stereoisomer thereof: wherein R1, R2, R3 and R4 are as defined in the present disclosure.

GLUCOSE METABOLISM MODULATING COMPOUNDS

The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyperglycemia.

Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents

Antagonism of αvβ6 is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an αvβ3 antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved αvβ6 activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan αv antagonists having ca. 100 nM potency against αvβ3, αvβ5, αvβ6, and αvβ8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC50 values between the integrins in question) for αvβ3 and αvβ5.

Facile synthesis of N-(9-fluorenylmethyloxycarbonyl)-3-amino-3-(4,5- dimethoxy-2-nitrophenyl)propionic acid as a photocleavable linker for solid-phase peptide synthesis

A photocleavable linker, N-(9-fluorenylmethyloxycarbonyl)-3-amino-3-(4,5- dimethoxy-2-nitrophenyl)propionic acid was synthesized from veratraldehyde, with simple reaction and separation steps. This linker was stable under the normal solid-phase peptide sy

Kinetic resolution of aromatic β-amino acids by ω-transaminase

Racemic aromatic β-amino acids have been kinetically resolved into (R)-β-amino acids with high enantiomeric excess (>99%) by a novel ω-TA with ca. 50% conversion.

HYPOGLYCEMIC DIHYDROPYRIDONES

The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods o

Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists

Vesicular monoamine transporter type 2 (VMAT2) is a newly emerging target for both diagnostic and therapeutic applications in diabetes mellitus. In pursuit of novel VMAT2 antagonists, we identified a potent hypoglycemic agent with a novel dihydropyridone

An efficient new enzymatic method for the preparation of β-aryl-β-amino acid enantiomers

An efficient synthesis of β-aryl-β-amino acid enantiomers has been developed via the lipase-catalysed enantioselective hydrolysis of the corresponding racemic ethyl esters in an organic solvent. High enantioselectivities (E >100) were observed when the lipase PS-catalysed reactions were performed with H2O (0.5 equiv) in diisopropyl ether at 45 °C. The products could be easily separated and were obtained in good yields of ≥40%.

Competitive formation of β-amino acids, propenoic, and ylidenemalonic acids by the Rodionov reaction from malonic acid, aldehydes, and ammonium acetate in alcoholic medium

The Rodionov reaction of 49 available aliphatic and aromatic aldehydes with malonic acid and ammonium acetate in alcoholic medium, resulting in formation of β-amino acids, propenoic, and ylidenemalonic acids, was studied. Certain regioselectivity regularities of the reaction were revealed. Among the variety of ketones studied, cyclohexanone is the only whose reaction yields a β-amino acid. Unusual dehydrofluorination of 6-chloro-2-fluorocinnamic acid under the Rodionov reaction was discovered. 2005 Pleiades Publishing, Inc.